Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HRH1 | P35367 | 4/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29133215 | 0.79 | MAOA (0.45) | MAOAMAOBHDAC9HTR2AHRH1 | |
| SCHEMBL21248511 | 0.77 | MAOB (0.38) | MAOAMAOBHDAC9HTR2AHRH1 | |
| SCHEMBL17867147 | 0.73 | ALDH1A1 (0.37) | MAOAMAOBALDH1A1 | |
| SCHEMBL2985677 | 0.73 | MAOA (0.35) | MAOAMAOBHDAC9HTR2AHRH1 | |
| SCHEMBL12083436 | 0.72 | SMN1; SMN2 (0.39) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL7783926 | 0.72 | MAOA (0.43) | MAOAMAOBNFKB1NFKB2RELA | |
| SCHEMBL31015957 | 0.72 | MAOA (0.43) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL28616256 | 0.72 | MAOA (0.43) | MAOAMAOBHTR2AHRH1HTR2B | |
| SCHEMBL29798795 | 0.72 | MAOA (0.43) | MAOAMAOBNFKB1NFKB2RELA | |
| SCHEMBL5138520 | 0.71 | MAOA (0.36) | MAOAMAOBHTR2AHRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4061765-A | LIVER DISORDERS | DR. MADAUS & CO. (DT) | 1977-12-06 | — | — | US | claimed |
| US-3994925-A | USEFUL TO ANTAGONIZE OR MITIGATE LIVER DAMAGE AND INFLAMMATION | DR. MADAUS & CO. (DT) | 1976-11-30 | — | — | US | claimed |
| US-20240298592-A1 | USE OF HIGHER ALIPHATIC ALCOHOL IN IMPROVING NITROGEN FIXING CAPACITY AND DROUGHT RESISTANCE CAPACITY OF LEGUMES | ZHUHAI RUNNONG SCIENCE AND TECHNOLOGY CO. LTD (CN) | 2024-09-12 | — | — | US | disclosed |
| CN-106511421-B | A method of purification milk thistle Flavone class compound | 江苏中兴药业有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-106511421-A | Method for refining flavonoid compounds in stems and leaves of silybum marianum | 江苏中兴药业有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-2430017-B1 | A method for preparing AMORPHOUS SILIBININ | MADAUS GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8614341-B2 | Amorphous silibinin for the treatment of viral hepatitis | EUROMED S.A. (ES) | 2013-12-24 | — | — | US | disclosed |
| EP-2307405-B1 | COMPOSITION OF FLAVANOLIGNAN AND AMINO ACID WITH IMPROVED WATER SOLUBILITY | AGRA GROUP AS (CZ) | 2013-10-02 | — | — | EP | disclosed |
| US-8426459-B2 | Composition of flavanolignan and amino acid with improved water solubility | AGRA GROUP, A.S. (CZ) | 2013-04-23 | — | — | US | disclosed |
| US-20120204289-A1 | Manipulation of flavonoid biosynthetic pathway | AGRICULTURE VICTORIA SERVICES PTY LTD. (AU) | 2012-08-09 | — | — | US | disclosed |
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | EUROMED S.A. (ES) | 2012-05-03 | — | — | US | disclosed |
| US-6020384-A | SOLID ORAL UNIT DOSAGE FORM; THERAPY OF LIVER DISORDERS | MADAUS AG (DE) | 2000-02-01 | — | — | US | disclosed |
| US-5906991-A | RELEASING AND ABSORPTION, SUSPENSION AND HEATING | DR. MADAUS GMBH & CO (DE) | 1999-05-25 | — | — | US | disclosed |
| US-5714473-A | CHEMOTHERAPY; MIXTURE WITH ALKALI METAL CITRATE | MADAUS AG (DE) | 1998-02-03 | — | — | US | disclosed |
| US-4871763-A | Method of treating liver diseases using pure silibinin | DR. MADAUS GMBH & CO. (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4368195-A | Method for the extraction of silymarin from plants | DR. MADAUS & CO. (DE) | 1983-01-11 | — | — | US | disclosed |
| US-4168318-A | LIVER DISORDERS, OXIDATION OF ALCOHOL TO KETONE | DR. MADAUS & CO. (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4081529-A | EXTRACTS FROM SILYBUM MARIANUM SEEDS, ANTIHEPATOXIC | INVERNI DELLA BEFFA S.P.A. (IT) | 1978-03-28 | — | — | US | disclosed |
| US-4061765-A | LIVER DISORDERS | DR. MADAUS & CO. (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3994925-A | USEFUL TO ANTAGONIZE OR MITIGATE LIVER DAMAGE AND INFLAMMATION | DR. MADAUS & CO. (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | CSTB, PYGL, CCNB1 | MAOA 4045/4885MAOB 713/4885HDAC9 3304/4885 |
| US-20240298592-A1 | USE OF HIGHER ALIPHATIC ALCOHOL IN IMPROVING NITROGEN FIXING CAPACITY AND DROUGHT RESISTANCE CAPACITY OF LEGUMES | MYB, LPCAT1, LPCAT3 | MAOA 1581/4885MAOB 1140/4885HDAC9 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.